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Methyl (1S,3R,3aS,6aR)-5-(2-fluorophenyl)-1-methyl-4,6-dioxo-3-(p-tolyl)octahydropyrrolo[3,4-c]pyrrole-1-
carboxylate 
 
 
 
Er = 61:39% 
[α]D = - 3.7 (c 1.1, CHCl3, 61:39 er from HPLC) 
Source of chirality: (Sa,R,R)-Binol derived phosphoramidite and 
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4-(tert-Butyl) 2-methyl (2R,4R,5R)-2-[(1H-pyrazol-1-yl)methyl]-5-(thiazol-2-yl)pyrrolidine-2,4-dicarboxylate 
 
 
Er = 93:7 
[α]D = + 7.7 (c 0.6, CHCl3, 93:7 er) 
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Er = 93:7 
[α]D = -8.0 (c 1, CH2Cl2, 93:7 er from HPLC) 
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Abstract:  The asymmetric 1,3-dipolar cycloaddition (1,3-DC) of an imino ester 5 with tert-butyl 
acrylate is catalyzed by a dual chiral silver(I) complex formed from a chiral phosphoramidite 14 
and the chiral silver(I) binolphosphate (R)-17. This reaction is selected to perform the synthesis of 
enantiomerically enriched key structure to access the third generation of GSK HCV inhibitors. The 
scope of this dual chiral catalytic system is analyzed employing different imino esters and 
dipolarophiles, and furtherly compared with the same cycloaddition reactions performed with  
chiral phosphoramidite 14·Ag(I) complex. 
 
Keywords: Cycloaddition · azomethine ylides · phosphoramidite · silver(I) · enantioselective · dual 
activation 
 
1. Introduction 
 
The enantioselective synthesis of pyrrolidines or proline derivatives constitutes a very 
important trend in organic chemistry due to the interest of them in many scientific fields.1 Since the 
biological and medicinal point of view, molecules possessing antibiotic, antitumor, analgesic, 
neuroexcitatory activities, etc., have been widely described. However, the development of antiviral 
compounds (commercially available or in clinical survey) constitutes one of the main applications 
of these skeletons.2,3 At this moment, many antiviral agents (used individually or in combination 
with another drugs) administrated to patients include a nitrogenated five-membered ring, for 
example, elbasvir, grazoprevir, velpatasvir, ombitasvir, paritaprevir, boceprevir, telaprevir and 
daclatasvir have been recently developed.4 The complex skeleton of these molecules contrast with a 
family of prolinate derivatives 1-3 (Figure 1) reported by GSK through successive evolutions.5 
These compounds act as polymerase inhibitors of the several strands of the virus responsible of the 
Hepatitis C. Besides, less amount of effective doses and reduced secondary effects converted these 
products in a promising treatment for hepatitis C virus (HCV) infected people.6,7 
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Figure 1.  Family of GSK HCV inhibitors. 
 
In our group, the asymmetric synthesis of the 1st  18,9 and 2nd generation 210 antiviral drugs 
employing diastereo-8 and enantioselective2,11 1,3-dipolar cycloaddition (as key-step) between the 
corresponding methyl iminoleucinate and a lactate derived acrylate,8 or this imino ester with tert-
butyl acrylate employing a chiral phosphoramidite-AgClO4 catalytic complex
8 or a chiral dimeric 
Binap-gold(I) complex,10 respectively, was developed. In both routes, the overall yields obtained 
were moderate to good and enantioselectivities were very high, especially in the case of the 2nd 
generation inhibitor (99% ee). In this work, we report the efforts dedicated to build 
enantioselectively the core heterocyclic ring precursor of the GSK 625433 polymerase inhibitor 312 
and also a brief study of the scope and versatility of the new developed catalyst will be disclosed.  
 
 
2. Results and discussion 
 
According to the classical retrosynthetic analysis of this family of compounds, we envisaged 
that the enantiomerically enriched cycloadducts endo-4 type were the key compounds to the access 
to antiviral agent 3. Initially, we designed two alternative approaches where the pyrazole ring was 
bonded in the starting imino ester (Scheme 1, eq. a) and a second retrosynthesis in which the 
pyrazole was introduced once the 1,3-DC occurred (Scheme 1, eq. b). Starting imino ester 5a could 
be generated, under mild conditions, from commercially available 3-(1-pyrazolyl)-L-alanine methyl 
ester hydrochloride but important amounts of the product, resulting from the β-elimination of 
pyrazole, were detected by 1H NMR spectroscopy. The non-asymmetric multicomponent 1,3-DC 
was then tested employing tert-butyl acrylate, 2-thiazolecarbaldehyde and the amino ester, 
furnishing the undesirable β-elimination product.13 This problem was overcome employing the 
route starting from O-TBDMS serine derivative (Scheme 1, eq. b). Stable imino ester 5b was much 
more appropriate to run the non-asymmetric cycloaddition and, in consequence, adequate to survey 
the enantioselective 1,3-DC. This imino ester 5b was obtained, in almost quantitative yield, by 
reaction of 2-thiazolecarbaldehyde with the known compound O-TBDMS serine methyl ester14 in 
DCM at room temperature for 19 h and it was employed in the cycloadditions without any other 
purification (see experimental part). 
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Scheme 1. Retrosynthetic analysis. 
 
 Many chiral ligands and silver salts were tested in 5 mol% loading (Scheme 2 and Table 1) 
but always using toluene as better solvent (not registered in Table 1). The cycloadditions performed 
at room temperature involving Binap 6 afforded very good conversions but with moderate 
enantioselections (Table 1, entries 1-3).15 The best silver salt was AgSbF6, which gave, at room 
temperature, the desired compound endo-4b as a 85:15 mixture of diastereoisomers in 85:15 
enantiomeric ratio (Table 1, entry 2). The lowering of the temperature was not beneficial for this 
transformation (Table 1, entry 3).16 Chiral ligands 7 and 8 did not improve the results achieved by 
Binap 6 and almost racemic compound endo-4b was isolated when AgOBz or AgSbF6 were 
combined with chiral ligands 9-13 (these results are not included in Table 1). Phosphoramidite 
(Sa,R,R)-14·AgTFA complex and the analogous one formed with AgSbF6 furnished identical 
conversions, diastereomeric and enantiomeric ratios (Table 1, entries 4 and 5). The analysis of the 
temperature was next studied (Table 1, entries 5-7) obtaining an increment of the diastereomeric 
ratio (up to 99:1, at -80 ºC) but with a moderate enantioselection (80:20 at the same temperature). 
Analogous H8-chiral complex 15·AgSbF6 was not suitable for inducing a very high 
enantiodiscrimination (Table 1, entry 8). Because of dimeric gold species (S,S)-16·TFA2 was 
effective in the synthesis of the second generation GSK-agents it was used at 0 ºC in the 
cycloaddition of tert-butyl acrylate and imino ester 5b. The reaction was almost complete after 48 h 
reaction time giving endo-4b as major diastereoisomer in 85:15 dr and modest enantioselection 
(78:26 er, Table 1, entry 9). (S,S)-16·(OBz)2 catalytic complex was not effective affording lower 
diastereomeric and enantiomeric ratios (Table 1, entry 10). However, the dual chiral catalyst 14·Ag-
(R)-17, formed by reaction of silver carbonate and chiral (R)-binol-phosphoric acid in toluene17 for 
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1 h followed by the addition of phosphoramidite 14, produced at room temperature endo-
cycloadduct 4b in excellent conversion and high diasteromeric and enantiomeric ratio (Table 1, 
entry 11). A lowering of the temperature to -20 ºC did not produce any significant amelioration of 
the enantiomeric ratio. The corresponding enantiomer ent-endo-4b was easily obtained by 
employing the enantiomeric chiral catalytic system such as it is shown in entry 12 of Table 1. The 
configuration of these two enantiomeric forms of the dual chiral silver complex resulted to be the 
matched combination for this transformation because the other two detailed in the last two entries of 
Table 1 afforded lower enantiomeric ratios although with excellent conversions. From these three 
last entries, the absolute configuration induced in cycloadducts is strongly dependent of the axial 
chirality of the phosphoramidite ligand.  
 
 
 
 
 
 Tetrahedron: Asymmetry  
7 
 
7 
Scheme 2. Chiral ligands employed in the optimization study. 
 
 
Table 1. Study of the reaction conditions for the synthesis of 4b. 
 
a Determined by 1H NMR of the crude reaction mixture. 10 h Reaction time. 
b Determined by HPLC using chiral stationary phase columns. 
c 48 h Reaction time. 
 
 
With compound endo-4b in hand (82% yield, 96:4 dr and 92:7 er) next three steps were 
carried out in a sequential manner (Scheme 3). First, TBDMS was removed using three equiv. of 
tetrabutylammonium fluoride (TBAF, 1 M solution in THF) at room temperature for 3 h. 
Mesylation of the alcohol in the absence of trimethylamine avoided undesirable ring expansion 
process and after 2 h at 0 ºC, sodium pyrazolide18 was added at 0 ºC. Cycloadduct endo-18 was 
isolated after flash chromatography in 32% overall yield from endo-4b. The final access to 
molecule 3 can be achieved following known procedures described for this family of HCV 
inhibitors.6,7,19  
 
Entry Catalyst T (ºC) Conv. (%)a dra erb 
1 6·AgTFA 25 >95 70:30 81:19 
2 6·AgSbF6 25 >95 85:15 85:15 
3 6·AgSbF6 0 >95 85:15 82:18 
4 14·AgTFA 25 >95 90:10 66:34 
5 14·AgSbF6 25 >95 93:7 65:35 
6 14·AgSbF6 -20 >95 95:5 69:31 
7 14·AgSbF6 -80  >95 99:1 80:20 
8 15·AgSbF6 25 >95 99:1 59:31 
9 16·(TFA)2 0c 90 90:10 78:26 
10 16·(OBz)2 0c 95 85:15 76:24 
11 14·Ag-(R)-17 25 >95 96:4 93:7 
12 (Ra,S,S)-14·Ag-(S)-17 25 >95 95:5 8:92 
13 (Ra,S,S)-14·Ag-(R)-17 25 >95 96:4 23:77 
14 14·Ag-(S)-17 25 >95 90:10 75:25 
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Scheme 3. Synthesis of the key enantiomer endo-18 to access GSK 625433 polymerase inhibitor 3   
 
 
 The determination of the absolute configuration and the scope of effectiveness of the 
double chiral activated complex 14·Ag-(R)-17 were studied simultaneously. Initially, N-
methylmaleimide (NMM) was allowed to react with imino ester 19 (Ar = Ph, R1 = H) under 
optimized reaction conditions yielding product 20a (Table 2, entry 1). The absolute configuration 
was assigned on the basis on the comparison of its retention time (HPLC using a chiral stationary 
phase column) with the retention time of the identical sample isolated from the reaction catalyzed 
by 14·AgClO4 complex.
8 This absolute configuration was confirmed by analyzing both HPLC and 
specific optical rotation data of all isolated compounds described in Table 2. The dual chiral catalyst 
14·Ag-(R)-17 and 14·AgClO4 chiral complex afforded similar results of 20b and 20c too (Table 2, 
entries 2 and 3). However, the presence of a substituent at the α-position of the imino ester 19 
caused steric difficulties to the bulky chiral entity of 14·Ag-(R)-17. Thus, when alanine, leucine and 
phenylalanine derived imino esters 19 were employed with different dipolarophiles the catalytic 
complex 14·AgClO4 afforded cycloadducts 20 in higher both diastereomeric and enantiomeric 
ratios, although chemical yields are similar using separately both catalytic complexes (Table 2, 
entries 4-6). It is noteworthy that compound 20d appeared as potential novel HIV-1 integrase 
inhibitor,20 and molecule 20e is the key building block for the synthesis of the HCV inhibitor 1.6,8 
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Scheme 4. Scope of the reaction.   
 
 
Table 2. Synthesis of cycloadducts 20 in the presence of 14·Ag-(R)-17 and comparison with the 
results obtained employing 14·AgClO4. 
 
a Determined by 1H NMR of the crude reaction mixture. 10 h Reaction time. 
b Determined by HPLC using chiral stationary phase columns for the endo-stereoisomer. 
c Reaction performed at room temperature. 
d Reaction performed at -20 ºC. 
e o-FPM = N-(o-fluorophenyl)maleimide. Compound 20d was not prepared in ref. 9. 
f Reaction performed at 0 ºC. 
 
 
3. Conclusions 
In this work, the modulation of the chiral catalyst 14·Ag-(R)-17 could be adapted to the 
effective approach of the imino ester and tert-butyl acrylate to access the enantiomerically enriched 
core of the antiviral agent GSK 625433 by first time. Dual chiral catalyst is very appropriate to 
achieve a high enantioselection in this transformation unlike to the result gave by 14·AgClO4 
     14·AgClO4 (ref. 9)  14·Ag-(R)-17 
Ent. R1 Ar Dipolarophile Structure 
Yield 
(%)a 
dra erb  
Yield 
(%)a 
dra erb 
1 H Ph NMM 
20a 
80c >98:2 >99:1  78c >98:2 90:10 
2 H Ph tert-Butyl 
acrylate 
20b 
80d >98:2 90:10  90c >98:2 90:10 
3 H Ph Diisopropyl 
fumarate 
20c 
81d >98:2 91:9  82d 90:10 89:11 
4 Me 4-Me(C6H4) o-FPMe 
 20d 
58c 95:5 61:39  58c 95:5 53:47 
5 Bui 2-Thienyl 
tert-Butyl 
acrylate 
 20e 
78d >98:2 94:6  81d 95:5 76:24 
6 Bn Ph NMM 
20f 
71f >98:2 95:5  67f 95:5 73:27 
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complex. In the case of glycine imino esters both catalysts exhibit a similar behavior in the 
enantioselective 1,3-DC with dipolarophiles, but for sterically hindered imino esters (derived from 
α-substituted amino acids) it is advisable the employment of 14·AgClO4 complex. 
 
 
4. Experimental Part 
 
4.1. General information 
Melting points were determined with a Reichert Thermowar hot plate apparatus and are uncorrected. 
Only the structurally most important peaks of the IR spectra (recorded whit a FT-IR 4100LE (JASCO) 
(PIKE MIRacle ATR) are listed. 1H NMR (300 MHz) and 13C NMR (75 MHz) spectra were obtained with a 
Bruker AC-300 by using CDCl3 as solvent and TMS as the internal standard, unless otherwise stated. Optical 
rotations were measured with a JASCO 2000 series. HPLC analyses were performed with a JASCO-2000 
series equipped with a chiral stationary phase column (detailed for each compound in the main text) by using 
mixtures of n-hexane/isopropyl alcohol as the mobile phase at 25 ºC. Low-resolution electron impact (EI) 
mass spectra were obtained with a Shimadzu QP-5000 by injection or DIP, and high-resolution mass spectra 
were obtained with a Finnigan VG Platform or a Finnigan MAT 95S. Analytical TLC was performed on 
Schleicher & Schuell F1400/LS  254 silica gel plates and the spots were visualized under UV light (λ = 254 
nm). Merck silica gel 60 (0.040-0.063 mm) was used for flash chromatography. 
 
4.2. Synthesis of imino ester 5b. 
 In a 10 mL flask was dissolved free O-TBDMS serine methyl ester14 (357 mg, 1.5 mmol) and 2-
thiazolecarbaldehyde (134 μL, 1.5 mmol) in anhydrous dichloromethane (10 mL) and magnesium sulfate 
(200 mg) was added. The reaction was stirred at room temperature overnight and the organic phase was 
washed with bine, dried and evaporated affording quantitatively the crude imine (492 mg, 1.5 mmol) as a 
pale yellow oil; IR (neat) max 1743 cm-1; 1H NMR δH: 0.01, 0.05 (2s, 6H, 2xMeSi), 0.85 (s, 9H, Me3C), 3.77 
(s, 3H, MeO), 3.94 (dd, J = 10.5, 7.9 Hz, 1H, CH2O), 4.16 (dd, J = 10.5, 5.3 Hz, 1H, CHCO2Me),  4.26 (dd, 
J = 7.9, 5.3 Hz, 1H, CH2O), 7.47, 7.93 (2d, J = 3.1, 2H, HC=CH), 8.48 (s, 1H, HC=N); 13C NMR δC: -5.4, -
5.3 (Me2Si), 18.2 (CMe3), 25.8 (CCH3), 52.3 (OMe), 63.5 (CH2), 74.1 (CHCO), 122.1 (CHN), 144.8 (CHS), 
158.4 (CNS), 166.3 (C=N), 170.1 (CO); MS (EI-GC) m/z: 328 (M+, 1%), 271(80), 241 (11), 211 (13), 165 
(42), 137 (100), 89 (51), 75 (77); HRMS calculated for C20H24N2O3SSi: 328.1277, found: 328.1266. 
 
4.3. General procedure for the enantioselective 1,3-DC using dual catalyst 14·Ag-(R)-17. Synthesis of 
compounds endo-4b and 20. 
In a 10 ml vial covered by aluminum foil, Ag2CO3 (2.8 mg, 0.01 mmol), (R)-Binol-phosphoric acid 
(7 mg, 0.02 mmol) and toluene (3 mL) were added and the resulting mixture was stirred at room temperature 
for 1 h. Phosphoramidite (Sa,R,R)-14 (10.8 mg, 0.02 mmol) was added and the reaction stirred for additional 
40 min. Then, the imino ester (0.4 mmol), the dipolarophile (0.4 mmol) and triethylamine (3 μL, 0.02 mmol) 
were added in this order and the reaction stirred at room temperature. The mixture was cooled at -10 ºC and 
the amino ester 2c (193 mg, 1 mmol), the corresponding maleimide 3 (1 mmol), and ethyl glyoxylate 1 
(ca.50% solution in toluene, 102 μL, 1.2 mmol) were slowly added in this order. The reaction was stirred for 
17 h. The solvent was evaporated and the crude product was purified purified by flash chromatography (n-
hexane:EtOAc), affording cycloadducts endo-4b and 20.  
 
4.4. 4-(tert-Butyl) 2-methyl (2R,4S,5R)-2-{[(tert-butyldimethylsilyl)oxy]methyl}-5-(thiazol-2-
yl)pyrrolidine-2,4-dicarboxylate (endo-4b). 
Sticky pale yellow oil, 119 mg (82%); [α]D
20 =  -8.0 (c = 0.8, CH2Cl2) for 93:7 er by HPLC 
(Chiralpak AD-H), n-hexane/i-PrOH: 90/10, (0.7 mL/min, λ 250 nm), tmay = 8.3 min, tmin = 9.2 min; IRmax: 
3345, 1727, 1677 cm-1; 1H RMN δH: 0.05, 0.09 (2s, 6H, Me2Si), 0.87 (s, 9H, Me3C), 1.19 (s, 9H, CO2CMe3), 
2.16 (dd, J = 13.7, 8.1 Hz, 1H, CO2MeCCH), 2.80 (dd, J = 13.7, 8.3 Hz, 1H , CO2MeCCH), 3.00 (br. S, 1H, 
NH), 3.40 (ddd, J = 8.3, 8.1, 7.5 Hz, 1H, CHCO2tBu), 3.64 (d, J = 9.5 Hz, 1H, CH2OTBDMS), 3.72 (s, 3H, 
CO2Me), 3.79 (d, J = 9.5 Hz , 1H, CH2OTBDMS), 4.93 (d, J = 7.5 Hz , NHCH), 7.24, 7.68 (2sd, J = 3.3 Hz, 
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2H, HC=CH); 13C RMN δC: -5.6, -5.4 (Me2Si), 18.2 (SiCMe3), 25.8 (SiCMe3), 27.7 (OCMe3), 33.6 (CCH2C), 
49.5 (CHCO2tBu), 52.3 (CO2Me), 61.5 (CHNH), 69.1 (CH2OSi), 70.1 (CCO2Me), 80.9 (OCMe3), 118.9 
(CHS), 142.3 (CHNCSTh), 170.3 (NCS), 171.5, 174.6 (2xCO2); MS (ESI) m/z: 456 (M+, 2%); HRMS for 
C21H36N2O5Si required: 456.2112; found: 456.2108.  
 
4.5. Methyl (1S,3R,3aS,6aR)-5-methyl-4,6-dioxo-3-phenyloctahydropyrrolo[3,4-c]pyrrole-1-
carboxylate (20a):9,21 90 mg, 78%; [𝛼]D
20 = +62.0 (c 1, CH2Cl2) for 90:10 er, [𝛼]D
20 = +61.0 (c 1.18, 
CH2Cl2) for 90:10 er.21 
 
4.6. 4-(tert-Butyl) 2-methyl (2S,4S,5R)-5-phenylpyrrolidine-2,4-dicarboxylate (20b):9,22 84 mg, 90%; 
[𝛼]D
20 = +22.5 (c 1.3, CH2Cl2) for 90:10 er, [𝛼]D
20 = ˗26.8 (c 1.3, CH2Cl2) for 3:97 er (opposite 
enantiomer).22 
 
4.7. 3,4-Diisopropyl 2-methyl (2S,3S,4S,5R)-5-phenylpyrrolidine-2,3,4-tricarboxylate (20c):9 66 mg, 
82%; [𝛼]D
20 = +30.9 (c 0.5, CHCl3) for 89:11 er, [𝛼]D
20 = +32.5 (c 0.5, CHCl3) for 91:9 er.9 
 
4.8. Methyl (1S,3R,3aS,6aR)-5-(2-fluorophenyl)-1-methyl-4,6-dioxo-3-(p-tolyl)octahydropyrrolo[3,4-
c]pyrrole-1-carboxylate (20d): pale yellow oil, 92 mg, 58%. [𝛼]D
20 = -3.5 (c 1.1, CHCl3) for 61:39 er by 
HPLC (Chiralpak OD-H), n-hexane/i-PrOH: 50/50, (1 mL/min, λ 250 nm), tmay = 9.7 min, tmin = 14.7 min; 
IRmax: 3370, 1771, 1690 cm-1; 1H RMN δH: 1.69 (s, 3H, MeCN), 2.32 (s, 3H, MeC6H4), 3.53 (d, J = 8.5 Hz, 
1H, CHCMe), 3.40 (br. S, 1H, NH), 3.77 (dd, J = 10.0, 8.5 Hz, 1H, CHCHN), 3.87 (s, 3H, OMe), 4.92 (d, J 
= 10.0 Hz, 1H , CHN), 7.15-7.45 (m, 8H, ArH); 13C RMN δC: 22.3 (MeC6H4), 28.6 (MeCN), 49.7,51.8 
(2xCHCO), 52.4 (CO2Me), 59.2 (CNMe), 64.0 (NHCH), 126.6, 126.8, 127.3, 127.4, 128.1, 128.4, 128.6, 
128.7, 129.0, 137.8 (ArC), 169.1, 170.3, 172.0 (3xCO); MS (EI) m/z: 395 (M+-1, 2%), 337 (45), 205 (100), 
172 (18), 157 (10), 145 (70), 104 (10); HRMS for C22H21FN2O4 – H (M+-1) required: 395.1407; found: 
395.1403.  
 
4.9. 4-(tert-Butyl) 2-methyl (2S,4S,5R)-2-isobutyl-5-(thiophen-2-yl)pyrrolidine-2,4-dicarboxylate (20e):9 
95 mg, 81%; [𝛼]D
20 = +23.2 (c 1, CHCl3) for 76:24 er, [𝛼]D
20 = +38.6 (c 1, CHCl3) for 94:6 er.9 
 
4.10. Methyl (1S,3R,3aS,6aR)-1-benzyl-5-methyl-4,6-dioxo-3-phenyloctahydropyrrolo[3,4-c]pyrrole-1-
carboxylate (20f):9 101 mg, 67%; [𝛼]D
20 = ˗35.2 (c 0.8, CHCl3) for 73:27 er, [𝛼]D
20 = ˗74.2 (c 0.8, CHCl3) 
for 95:5 er.9 
 
4.11. Synthesis of 4-(tert-Butyl) 2-methyl (2R,4S,5R)-2-[(1H-pyrazol-1-yl)methyl]-5-(thiazol-2-
yl)pyrrolidine-2,4-dicarboxylate (endo-18).  
Compound endo-4b (264 mg, 0.58 mmol) was dissolved in anhydrous in THF and 
tetrabutylammonium fluoride (1M solution in THF) was added (1.75 mL, 1.75 mmol) at 0 ºC, and the 
reaction was stirred at room temperature for three hours. The solvent was evaporated and ethyl acetate (10 
mL) was added. The resulting solution was washed with bine, died and evaporated affording the intermediate 
alcohol, which was dissolved in anhydrous THF (5 mL). This new solution was cooled at 0 °C, triethylamine 
(89 μL, 0.64 mmol) was added and methanesulfonyl chloride was slowly introduced (54 μL, 0.64 mmol) and 
stirring continued for two hours at the same temperature. At this moment, a 1:1 anhydrous DMF:THF 
solution (3 mL) containing sodium pyrazolide [1.75 mmol, obtained by mixing pyrazole (118 mg, 1.75 
mmol) with sodium hydride (95%, 42 mg, 1,75 mmol)] was added and the reaction stirred at room 
temperature for 24 h. The solvent was evaporated and the residue purified by flash chromatography (n-
hexane:EtOAc), affording cycloadduct endo-18 as a pale yellow oil (70 mg, 32% overall yield). [α]D
20 =
 +7.7 (c 0.6, CHCl3) 93:7 er; IR max 3065, 1728 cm-1; 1H NMR δH: 1.44 (s, 3H, CMe3), 2.10 (dd, J = 10.8, 
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8.8 Hz, 1H, CCH2C), 2.58 (dd, J = 13.0, 8.8 Hz, 1H, CCH2C), 3.15 (m, 1H, CHCO), 3.65-372 (m with s at 
3.73, 5H, NH, CH2N, OMe), 3.86 (d, J = 10.6 Hz, 1H, CH2N), 4.86 (d, J = 8.5 H, 1H, H, CHN), 7.26 (m, 3H, 
CHCHNN, CHS), 7.64 (m, 2H, 2xC=CHN);  13C NMR δC: 27.9 (CMe3), 29.7 (CCH2C), 52.1 (CHCO), 52.3 
(OMe), 62.5 (CHNH), 67.3 (CH2N), 70.2 (NCCO), 81.3 (CMe3), 100.0 (CHCHNN), 119.1 (CHS), 128.1 
(CHNN), 129.1 (CHNN), 142.5 (CHNCS), 171.5, 171.6, 174.5 (NCS, 2xCO);   MS (EI-GC) m/z: 392 (M+, 
5%), 383 (10), 343 (15), 311 (24), 255 (100), 86 (13), 73 (13); HRMS calculated for C18H24N4O4S: 
392.1518, found: 392.1509. 
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